- Top Workplaces
- Dyax Corp.
Dyax's mission is to develop and commercialize innovative biopharmaceuticals for unmet medical needs while delivering value to patients, shareholders and employees. The Company works to fulfill this mission by marketing KALBITOR® (ecallantide), its FDA approved product for the rare disease hereditary angioedema (HAE), and through its commitment to developing DX-2930, a potential prophylactic treatment for HAE. Dyax is also working to identify and develop additional treatments for other rare disorders. Both KALBITOR and DX-2930 were identified using Dyax's proprietary phage display technology. Dyax has broadly licensed this technology under its Licensing and Funded Research Portfolio (LFRP). The current portfolio includes one FDA approved product, Eli Lilly and Company’s CYRAMZA® (ramucirumab), for which Dyax receives royalties, and multiple product candidates in various stages of clinical development for which the Company is eligible to receive future royalties.